In April 2026, the FDA finalized the removal of BPC-157 and TB-500 (Thymosin Beta-4) from the Category 2 bulk drug substances list under 503A and 503B compounding frameworks. This is a significant development for any clinic that has been incorporating these peptides into physician-supervised protocols. Here is what happened, why it matters, and what the most compliant clinic operators are doing right now.
What Is the Category 2 List?
The FDA's Category 2 list represents bulk drug substances nominated for potential inclusion on the 503A and 503B positive lists — meaning they were candidates to be compounded legally by licensed compounding pharmacies. Substances on Category 2 were in a regulatory gray area: they had been nominated but not yet evaluated, and compounding continued while the agency worked through its review queue.
Category 1 substances have been evaluated and are currently under consideration for inclusion. Category 2 substances are nominated but not yet reviewed. Removal from Category 2 is not the same as being placed on a "do not compound" list — but it does signal that the FDA has evaluated the nomination and declined to move it forward, or has identified concerns that warrant removal.
What the April 2026 Decision Actually Means
The FDA's action removes BPC-157 and TB-500 from the pool of substances that compounding pharmacies may use as bulk ingredients for 503A and 503B purposes. Practically, this means that licensed 503A compounding pharmacies may no longer legally compound these substances for patient-specific prescriptions, and 503B outsourcing facilities may no longer produce them for office use.
It does not mean that research-grade BPC-157 or TB-500 distributed by registered research chemical suppliers becomes illegal overnight for all purposes. The key distinction is the intended use and the regulatory framework under which the substance is being distributed. Physician-supervised clinical research protocols — in which a licensed provider is directing use for research purposes and documenting outcomes — operate under a different framework than prescription compounding.
What Compliant Clinics Are Doing
The question is not whether to remove these peptides from your practice. The question is how to continue offering meaningful outcomes to your patients within an updated compliance framework.
Clinics that operated with clean documentation practices before April 2026 are in the strongest position. If your protocols characterized these peptides as research-grade, directed by a licensed physician, and documented as part of a clinical research framework, the operational impact is manageable.
1. Update Patient Consent and Informed Disclosure Language
Every patient-facing document that references BPC-157 or TB-500 should be reviewed. Any language that implied these substances were FDA-approved pharmaceuticals — as opposed to research-grade peptides used under physician direction — should be corrected immediately.
2. Review Your Sourcing Relationships
The FDA action applies specifically to 503A/503B compounding. Research-grade peptide distributors who operate as registered suppliers of research chemicals — not as compounding pharmacies — are in a different regulatory category. Confirm with your current supplier whether their distribution model is affected by the April 2026 decision.
3. Audit Your Marketing and Intake Materials
Remove any claims that peptides treat, cure, or prevent specific conditions. This has always been a compliance requirement; the April 2026 decision makes enforcement more likely and gives regulators a clear framework to reference.
4. Document Protocol Rationale
If you continue to offer BPC-157 or TB-500 as part of physician-supervised research protocols, your chart documentation should clearly reflect the research nature of the protocol, the informed consent discussion, and the physician's clinical rationale.
What's Next: The July 2026 PCAC Hearing
The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to hear additional testimony in July 2026 regarding several peptides currently under evaluation. The outcome of that hearing will shape the compounding landscape for BPC-157, TB-500, and related peptides for the foreseeable future.
Clinic operators who want to stay ahead of this should be tracking PCAC agendas, which are published on the FDA website in advance of each meeting. Industry groups including ACAM and the American Academy of Anti-Aging Medicine (A4M) are submitting formal comments and may be worth monitoring for updates.
The Bottom Line for Your Clinic
The April 2026 FDA action is significant but not a business-ending event for clinics that have been operating with proper documentation and compliance-forward protocols. The window for operating under informal practices has closed. Clinics that pivot quickly to clear, well-documented research frameworks — and that work with compliant distributors — are well positioned for what comes next.
Golden Lotus Labs distributes research-grade peptides exclusively to licensed healthcare providers under documented physician-supervised protocols. Our compliance team is available to help partner clinics review their existing documentation and transition smoothly through the current regulatory environment.